ArticleVirchows Archiv : an international journal of pathology2026
Pathologic features and biomarker profiles of microinvasive breast carcinoma diagnosed on core needle biopsy with excision correlation.
Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to describe the pathologic features and biomarker profiles of a large microinvasive breast carcinoma (MiBC) cohort diagnosed on biopsy (CNB) and compare these findings with corresponding tumors on excision. Out of 263 MiBC, approximately half of the DCIS cases were classified as high-grade. On CNB, ER, PR, and HER2 were positive in 166/226 (73%), 124/225 (55%), and 48/174 (28%) of the tested cases, respectively. Excision specimens from 132 cases revealed invasive carcinoma in 52/132 (39%), MiBC in 31/132 (23%), DCIS only in 35/132 (27%), LCIS only in 4/132 (3%), and benign findings in 10/132 (8%). The concordance rates between CNB and excision were initially 100% for ER (40/40), 95% for PR (38/40), and 90% for HER2 (26/29). While routine retesting of ER/PR may not be necessary in cases of MiBC on CNB, selective repeat HER2 testing should be considered when larger tumors are present on excision.
Indexed as
Identifiers
41528428What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.